HALUK YUZUGULLU
HALUK YUZUGULLU
Astrazeneca Pharmaceuticals
Verified email at astrazeneca.com
Title
Cited by
Cited by
Year
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
HYJJZ Lauren M. Thorpe
Nature Reviews Cancer 15 (1), 7–24, 2014
946*2014
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
JJZ Shom Goel, Qi Wang, April C. Watt, Sara M. Tolaney, Deborah A. Dillon ...
Cancer Cell 29 (3), p255–269, 2016
2832016
CDK7-dependent transcriptional addiction in triple-negative breast cancer
Y Wang, T Zhang, N Kwiatkowski, BJ Abraham, TI Lee, S Xie, H Yuzugullu, ...
Cell 163 (1), 174-186, 2015
2782015
Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells
H Yuzugullu, K Benhaj, N Ozturk, S Senturk, E Celik, A Toylu, N Tasdemir, ...
Molecular cancer 8 (1), 1-20, 2009
2492009
Senescence and immortality in hepatocellular carcinoma
M Ozturk, A Arslan-Ergul, S Bagislar, S Senturk, H Yuzugullu
Cancer letters 286 (1), 103-113, 2009
992009
Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation
O Gursoy‐Yuzugullu, H Yuzugullu, M Yilmaz, M Ozturk
Liver International 31 (4), 561-571, 2011
712011
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.
SP Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE ...
Cancer Cell 31 (4), 576–590, 2017
702017
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α
K Gritsman, H Yuzugullu, T Von, H Yan, L Clayton, C Fritsch, SM Maira, ...
The Journal of clinical investigation 124 (4), 1794-1809, 2014
572014
Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis
G Yildiz, A Arslan-Ergul, S Bagislar, O Konu, H Yuzugullu, ...
PloS one 8 (5), e64016, 2013
512013
A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis
H Yuzugullu, L Baitsch, T Von, A Steiner, H Tong, J Ni, LK Clayton, ...
Nature communications 6 (1), 1-13, 2015
372015
The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity
M Mumcuoglu, S Bagislar, H Yuzugullu, H Alotaibi, S Senturk, ...
PloS one 5 (6), e11288, 2010
242010
NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways
H Yuzugullu, T Von, LM Thorpe, SR Walker, TM Roberts, DA Frank, ...
Cell discovery 2 (1), 1-13, 2016
142016
Evaluation of ATAD2 As a Potential Target in Hepatocellular Carcinoma
U Ekin, H Yuzugullu, C Ozen, P Korhan, E Bagirsakci, F Yilmaz, ...
2021
Development of a second-generation TRAIL agonist and predictive biomarker profile for colorectal cancer
S Ghassemifar, Y Hashambhoy-Ramsay, H Yuzugullu, T Utermark, ...
Cancer Research 79 (13), 2019
2019
Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
D Tamara, S Ghassemifar, Y Hashambhoy-ramsay, DHC MARCANTONIO, ...
US Patent App. 16/305,289, 2019
2019
INVESTIGATION OF CAUSATIVE AGENTS IN COMMUNITY-ACQUIRED ATYPICAL PNEUMONIA CASES
E ÇALIŞKAN, Ş ÖKSÜZ, C ÖZTÜRK, I Sahin, O Kilincel, N Akar, ...
2019
MM-161, a first-in-class pan-FGFR antibody
T Dake, G Finn, M Geddie, N Kohli, M Razlog, L Xu, V Paragas, ...
Cancer Research 77 (13 Supplement), 22-22, 2017
2017
Targeted Therapy for Hepatocellular Carcinoma: What`s New?
H Yuzugullu, O Gursoy-Yuzugullu
Liver Res Open J 1 (1), e1-e3, 2015
2015
PI3K-p110β is required for leukemic transformation and HSC depletion in the absence of Pten
H Yuzugullu, L Baitsch, A Steiner, LK Clayton, K Gritsman, JJ Zhao
Cancer Research 74 (19 Supplement), 4775-4775, 2014
2014
Genome-Wide Transcriptional Reorganization Associated with Senescence-to
G Yildiz, A Arslan-Ergul, S Bagislar, O Konu, H Yuzugullu
2013
The system can't perform the operation now. Try again later.
Articles 1–20